Get the Stockscreener App
1.955
4.67%
-0.095
Bioxcel Therapeutics Inc stock is traded at $1.955, with a volume of 489.36K.
It is down -4.67% in the last 24 hours and down -22.75% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$2.05
Open:
$2
24h Volume:
489.36K
Relative Volume:
0.05
Market Cap:
$31.30M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.3184
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-14.29%
1M Performance:
-22.75%
6M Performance:
+9.79%
1Y Performance:
+203.89%
1-Day Range:
$1.91
$2.00
1-Week Range:
$1.91
$2.288
52-Week Range:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.955 | 40.28M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Why BioXcel Therapeutics Inc. stock could see breakout soonWeekly Investment Summary & Accurate Trade Setup Notifications - newser.com
What dividend safety score for BioXcel Therapeutics Inc. stockWall Street Watch & Risk Managed Investment Signals - newser.com
Can BioXcel Therapeutics Inc. stock beat market expectations this quarter2025 Performance Recap & Community Trade Idea Sharing - newser.com
Does BioXcel Therapeutics Inc. show high probability of reboundQuarterly Market Summary & Low Risk High Reward Trade Ideas - newser.com
Will BioXcel Therapeutics Inc. stock benefit from automationPortfolio Value Summary & High Yield Stock Recommendations - newser.com
Published on: 2025-11-03 01:00:44 - newser.com
How BioXcel Therapeutics Inc. stock reacts to Fed rate cutsCEO Change & Weekly Return Optimization Alerts - newser.com
Why BioXcel Therapeutics Inc. stock remains on buy listsJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Tools to monitor BioXcel Therapeutics Inc. recovery probabilityQuarterly Earnings Summary & Fast Momentum Entry Tips - newser.com
Why BioXcel Therapeutics Inc. stock remains a top recommendationGap Up & Low Risk Entry Point Guides - newser.com
Published on: 2025-11-02 05:48:35 - newser.com
Is BioXcel Therapeutics Inc. (BX20) stock bottoming after sell off2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Published on: 2025-11-01 08:49:34 - newser.com
Can you recover from losses in BioXcel Therapeutics Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - newser.com
How analysts revise price targets for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 EndofMonth & Precise Swing Trade Entry Alerts - newser.com
Leading vs lagging indicators on BioXcel Therapeutics Inc. performanceVolume Spike & Real-Time Stock Price Movement Reports - newser.com
BTAI sets Dec 12 virtual annual meeting; board backs all items - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
Will BioXcel Therapeutics Inc. benefit from macro trendsAnalyst Upgrade & Daily Profit Focused Stock Screening - newser.com
How BioXcel Therapeutics Inc. (BX20) stock reacts to stronger dollarBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Key metrics from BioXcel Therapeutics Inc.’s quarterly dataDay Trade & AI Enhanced Execution Alerts - newser.com
Building trade automation scripts for BioXcel Therapeutics Inc.2025 Risk Factors & Growth Focused Investment Plans - newser.com
BioXcel Therapeutics Updates sNDA Timeline for IGALMI® - MSN
BioXcel Therapeutics Updates on IGALMI® sNDA Submission - TradingView
BioXcel Therapeutics IncUpdates On sNDA Submission For IGALMI Label ExpansionSEC Filing - TradingView
Will BioXcel Therapeutics Inc. (BX20) stock recover faster than industryJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Published on: 2025-10-30 01:42:19 - newser.com
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):